Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GPX4 | P36969 | 9/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21725122 | 0.80 | ALDH1A1 (0.57) | ALDH1A1GAAMAPK1HSD17B10RAB9A | |
| SCHEMBL15478022 | 0.79 | CACNA2D1 (0.36) | ALDH1A1MAPK1RAB9AKDM4ENPC1 | |
| SCHEMBL12263521 | 0.79 | HSD17B10 (0.49) | TDP1ALDH1A1GAAMAPK1HSD17B10 | |
| SCHEMBL12245073 | 0.79 | HRH3 (0.52) | ALDH1A1GAAMAPK1HSD17B10RAB9A | |
| SCHEMBL21737951 | 0.78 | ALDH1A1 (0.61) | ALDH1A1GAAMAPK1HSD17B10RAB9A | |
| SCHEMBL2397484 | 0.78 | ALDH1A1 (0.66) | TDP1ALDH1A1GAAMAPK1HSD17B10 | |
| SCHEMBL21738073 | 0.76 | GAA (0.36) | ALDH1A1GAAMAPK1HSD17B10RAB9A | |
| SCHEMBL21738056 | 0.76 | HDAC3 (0.52) | TDP1ALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL16982109 | 0.76 | POLB (0.42) | TDP1GPX4POLB | |
| SCHEMBL25859539 | 0.75 | RAB9A (0.42) | ALDH1A1GAAMAPK1HSD17B10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | TDP1 933/4885ALDH1A1 2989/4885GAA 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.